Paper6437469
Progress in gall stone disease.
Bateson MC. Br Med J (Clin Res Ed), 1984. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Progress in gall stone disease. Papers, record 6437469. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6437469
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cholelithiasis | Major topic |
| Female | |
| Humans | |
| Male | |
| Ultrasonography | |
| Ursodeoxycholic Acid |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 685927 | Clofibrate therapy and gallstone induction. | Am J Dig Dis | 1978 | https://conductscience.org/library/papers/685927 | PubMed |
| 2 | 7380174 | Monooctanoin, a dissolution agent for retained cholesterol bile duct stones: physical properties and clinical application. | Gastroenterology | 1980 | https://conductscience.org/library/papers/7380174 | PubMed |
| 3 | 6109120 | Intraductal infusion of mono-octanoin: experience in 24 patients with retained common-duct stones. | Lancet | 1981 | https://conductscience.org/library/papers/6109120 | PubMed |
| 4 | 7053334 | Estrogen predisposes to cholecystectomy but not to stones. | Gastroenterology | 1982 | https://conductscience.org/library/papers/7053334 | PubMed |
| 5 | 6119557 | Is recurrence inevitable after gallstone dissolution by bile-acid treatment? | Lancet | 1982 | https://conductscience.org/library/papers/6119557 | PubMed |
| 6 | 7060825 | Gallstone dissolution after 6 months of ursodeoxycholic acid (UDCA): effectiveness of different doses. | J Int Med Res | 1982 | https://conductscience.org/library/papers/7060825 | PubMed |
| 7 | 6803946 | Gall-stone dissolution and recurrence: are we being misled? | Br Med J (Clin Res Ed) | 1982 | https://conductscience.org/library/papers/6803946 | PubMed |
| 8 | 7110244 | The natural history of silent gallstones: the innocent gallstone is not a myth. | N Engl J Med | 1982 | https://conductscience.org/library/papers/7110244 | PubMed |
| 9 | 7051912 | Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. | Ann Intern Med | 1982 | https://conductscience.org/library/papers/7051912 | PubMed |
| 10 | 7140487 | Gallstone dissolution rate during chenic acid therapy. Effect of bedtime administration plus low cholesterol diet. | Dig Dis Sci | 1982 | https://conductscience.org/library/papers/7140487 | PubMed |
| 11 | 7141392 | Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study. | Hepatology | 1982 | https://conductscience.org/library/papers/7141392 | PubMed |
| 12 | 6345281 | Medical treatment of biliary duct stones: effect of ursodeoxycholic acid administration. | Gut | 1983 | https://conductscience.org/library/papers/6345281 | PubMed |
| 13 | 6873581 | [Recurrence and prevention of recurrence after dissolution of gallbladder lithiasis by chenodeoxycholic acid in 22 patients]. | Gastroenterol Clin Biol | 1983 | https://conductscience.org/library/papers/6873581 | PubMed |
| 14 | 6881778 | Prophylactic cholecystectomy or expectant management for silent gallstones. A decision analysis to assess survival. | Ann Intern Med | 1983 | https://conductscience.org/library/papers/6881778 | PubMed |
| 15 | 6884818 | Nucleation of cholesterol monohydrate crystals from hepatic and gall-bladder bile of patients with cholesterol gall stones. | Gut | 1983 | https://conductscience.org/library/papers/6884818 | PubMed |
| 16 | 6690352 | Supersaturated bile from obese patients without gallstones supports cholesterol crystal growth but not nucleation. | Gastroenterology | 1984 | https://conductscience.org/library/papers/6690352 | PubMed |
| 17 | 6364909 | Low-dose chenodiol to prevent gallstone recurrence after dissolution therapy. | Ann Intern Med | 1984 | https://conductscience.org/library/papers/6364909 | PubMed |
| 18 | 6364910 | Additional chenodiol therapy after partial dissolution of gallstones with two years of treatment. | Ann Intern Med | 1984 | https://conductscience.org/library/papers/6364910 | PubMed |
| 19 | 6671484 | Ursodeoxycholic acid for the dissolution of radiolucent gall bladder stones. | Digestion | 1983 | https://conductscience.org/library/papers/6671484 | PubMed |
| 20 | 6706305 | Franco-Belgian cooperative study of ursodeoxycholic acid in the medical dissolution of gallstones: a double-blind, randomized, dose-response study, and comparison with chenodeoxycholic acid. | Hepatology | 1984 | https://conductscience.org/library/papers/6706305 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 3906614 | Review of general surgery 1984-85. | Postgrad Med J | 1985 | https://conductscience.org/library/papers/3906614 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6437469
GET https://conductscience.org/api/papers/v1/6437469/references?page=2